2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester has been researched along with aclidinium bromide in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alcaraz, L; Bailey, A; Bowers, K; Donald, D; Edwards, H; Hunt, F; Kindon, N; Pairaudeau, G; Stocks, MJ; Theaker, J; Warner, DJ | 1 |
Bowers, K; Chevalier, E; Donald, DK; Edwards, H; Escott, KJ; Ford, R; Grime, K; Mete, A; Millichip, I; Russell, V; Teobald, B | 1 |
Bowers, K; Bull, RJ; Coope, H; Donald, DK; Escott, KJ; Ford, R; Grime, K; Mather, A; Mete, A; Ray, NC; Russell, V | 1 |
3 other study(ies) available for 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester and aclidinium bromide
Article | Year |
---|---|
The discovery of new spirocyclic muscarinic M3 antagonists.
Topics: Animals; Drug Evaluation, Preclinical; Hepatocytes; Humans; Microsomes; Rats; Receptor, Muscarinic M3; Spiro Compounds | 2010 |
The discovery of AZD9164, a novel muscarinic M3 antagonist.
Topics: Blood Proteins; Drug Evaluation, Preclinical; Humans; Muscarinic Antagonists; Piperidines; Protein Binding; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Receptor, Muscarinic M3; Structure-Activity Relationship | 2011 |
The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD.
Topics: Administration, Inhalation; Animals; Bronchoconstriction; Cycloheptanes; Disease Models, Animal; Guinea Pigs; Humans; Molecular Structure; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Receptors, Muscarinic | 2013 |